Pharmacopeia
VERAPAMIL
Core pharmacology
- Introduction
Phenylalkylamine
(Non-dihydropyridine calcium channel blocker)Synthetic papaverine derivative
- Indications Uses
HTN
Angina
Paroxysmal SVT and AFib/Aflutter- Mechanism of action
Binds to V binding site of L-type channel.
Levoisomer: main effects (arterial vasodilation). Slows conduction through the AV and SA node to a greater extent than other CCBs.
Dextro: Only acts on fast sodium channels, accounting for local anesthetic effects (1.6x potent as procaine)- Protein binding
~90%
- Volume of distribution
3.89 L/kg
- Metabolism
Hepatic via multiple CYP isoenzymes, one active metabolite with 20% activity
- Excretion
Urine (70% metab, 3% to 4% unchanged); feces (16%)
- Half-life
3-7 hours
- Route And Dose
40mgPO or 5-10mg IV.
- Chemical Pharmaceutics
Racemic mixture.
- Onset Peak Duration
on/ dur 1-2 hrs / 6-8 hrs (PO)
- Class Group
Non-dihydropyridine calcium-channel blocker; Vaughan Williams class IV antiarrhythmic.
- Presentation
Available in oral immediate/modified-release formulations and as an IV preparation; exact strengths vary by product.
- Absorption
Completely absorbed orally. Oral bioavailability 10-22% because of significant first-pass metabolism.
- Physiological effects
CVS: slow conduction of AP at SA and AV node, negatively inotropic, peripheral vasodilation (↓SVR), arrhythmia (heart block, VF in WPW). CNS: ↑CBF, may potentiate effects of depol/NDMBs. GIT - Constipn/Nausea
- Adverse Effects Toxicity
Dizziness, nausea, flushing, postural hypotension.
in patients without CCF: ↑LV fn by improving ischemia. In pts with CCF: ↓contractility and LV fn. Should be avoided in pts with WPW- cause VT/VF.
Inhibits CYP3A4.